Market Overview

Aegis Capital Initiates Coverage on Sinovac Biotech, Ltd. at Hold, Announces $2.50 PT

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for SVA

DateFirmActionFromTo
Mar 2014Morgan StanleyUpgradesOverweight
Nov 2013Aegis CapitalReiteratesBuy
Aug 2013Aegis CapitalUpgradesHoldBuy

View More Analyst Ratings for SVA
View the Latest Analyst Ratings

Posted-In: News Analyst Ratings

 

Related Articles (SVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters